Profile: Pfizer Inc (PFE)
24 Nov 2015
Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company's portfolio includes medications and vaccines, as well as consumer healthcare products. Its key biopharmaceutical products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, the Premarin family of products, Eliquis and Xeljanz, among others. The Company's biotechnology products include BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel, among others.
The Company's commercial operations consist of two businesses: Innovative Products business and Established Products business. The Innovative Products business consists of two operating segments: the Global Innovative Pharmaceutical segment (GIP) and the Global Vaccines, Oncology and Consumer Healthcare segment (VOC). The Established Products business consists of the Global Established Pharmaceutical segment (GEP). Its research focuses on six areas, which include immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases. In addition, it focuses on biosimilars. The Company has collaboration and/or co-promotion agreements relating to certain biopharmaceutical products, including Aricept, Enbrel (in the United States and Canada), Spiriva and Rebif. In addition, the Company developed Eliquis in collaboration with Bristol-Myers Squibb Company (BMS). The Company's subsidiary is Hospira, Inc.
The Company's Consumer Healthcare business is an over-the-counter (OTC) and healthcare products business that produces two of the Company's consumer healthcare brands (Centrum and Advil). The Consumer Healthcare business focuses on various geographic markets, such as the United States, China, Canada, Germany, Italy and Brazil. The categories and product lines in its Consumer Healthcare business include: dietary supplements, pain management, gastrointestinal, respiratory and personal care. Dietary supplements include Centrum brands, including Centrum, Centrum Silver, Centrum Men's and Women's, Centrum Specialist, Centrum Flavor Burst, and Centrum Kids; Caltrate, and Emergen-C. Pain management category includes Advil brands, including Advil, Advil PM, Advil Liqui-Gels, Advil Film Coated, Children's Advil, Infants' Advil and Advil Migraine, and ThermaCare. Gastrointestinal includes Nexium 24HR/Nexium Control. Respiratory category includes Robitussin, Advil Cold & Sinus, Advil Congestion Relief and Dimetapp. Personal care category includes ChapStick and Preparation H. The Company's Consumer Healthcare products are sold through various channels, including distributors, pharmacies, retail chains, and grocery and convenience stores.
Global Innovative Pharmaceutical segment
The Company's Global Innovative Pharmaceutical segment is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women's/men's health and include brands, such as Xeljanz, Eliquis and Lyrica (the United States and Japan). GIP has a pipeline of medications in inflammation, cardiovascular/metabolic disease, neuroscience and pain, and rare diseases.
Global Vaccines, Oncology and Consumer Healthcare segment
The Company's Global Vaccines, Oncology and Consumer Healthcare segment focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. Consumer Healthcare manufactures and markets several OTC products.
Global Established Pharmaceutical segment
The Company's Global Established Pharmaceutical segment includes the brands that have lost market and, generally, the mature, patent-protected products that are expected to lose exclusivity through 2015 in markets and, to a smaller extent, generic pharmaceuticals. Additionally, GEP includes its sterile injectable products and bio similar development portfolio.
235 E 42ND ST
NEW YORK NY 10017-5703
Company Web Links
- Pfizer's Lyrica shows no relief from post-traumatic nerve pain
- Pfizer Reports Top-Line Results from a Phase 3 Study of LYRICA® (pregabalin) Capsules CV in Adults with Post-Traumatic Peripheral Neuropathic Pain
- Merck KGaA, Darmstadt, Germany, and Pfizer Receive Positive Opinion for Orphan Drug Designation for Avelumab in Merkel Cell Carcinoma from EMA Committee for Orphan Medicinal Products
- Pfizer Receives European Approval to Expand Use of XALKORI® (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer
- CORRECTED-TIMELINE-Saunders gets key job as Pfizer, Allergan combine (Nov. 23)